Previous 10 | Next 10 |
Gainers: Incannex Healthcare Limited (NASDAQ:IXHL) +271%. Esperion Therapeutics (NASDAQ:ESPR) +10%. GitLab (NASDAQ:GTLB) +9%. Niu Technologies (NASDAQ:NIU) +7%. Lordstown Motors (NASDAQ:RIDE) +6%. Losers: Coupa Software Incorporated (NASDAQ:COUP) -29%. AnaptysB...
H.C. Wainwright has started the coverage on Esperion Therapeutics (ESPR +2.7%) with a Buy recommendation on Thursday, citing the commercial-stage pharma company’s lead products Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe). The oral non-statin cholesterol-loweri...
The following slide deck was published by Esperion Therapeutics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Esperion Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
Esperion Therapeutics recently reported their Q4 and full-year 2021 earnings. NEXLETOL and NEXLIZET together secured $12.2M in U.S. net product revenue, which is up 200% for the year. The company revealed improved commercial metrics including that scripts increased 9% over Q3 and that...
ANN ARBOR, Mich., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Chief Medical Officer, Dr. JoAnne Foody, will participate in a Cardiometabolic/NASH focused panel, in addition to one-on-one investor meetings with other members of management, at the upcoming C...
Esperion Therapeutics, Inc. (ESPR) Q4 2021 Earnings Conference Call February 22, 2022 08:00 AM ET Company Participants Ben Church - Investor Relations & Corporate Communications Sheldon Koenig - President & Chief Executive Officer Rick Bartram - Chief Financial Officer Eric Warren - H...
Image source: The Motley Fool. Esperion Therapeutics (NASDAQ: ESPR) Q4 2021 Earnings Call Feb 22, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Esperion Therapeutics (ESPR) Q4 2021 Earnings Call Transcript
Esperion (ESPR +11.5%) stock rose following its Q4 results which beat analysts' estimates. FY 2021 net product sales grew 208.89% Y/Y to ~$40.05M. U.S. The company said Net Product Revenue of NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and ezetimibe) tablets incre...
Esperion Therapeutics press release (NASDAQ:ESPR): Q4 GAAP EPS of -$1.77 beats by $0.52. Revenue of $15.4M (+59.8% Y/Y) beats by $0.92M. As of December 31, 2021, cash, cash equivalents, restricted cash and investment securities available-for-sale totaled $309.3 million compared with $305.0 mi...
– Unprecedented CLEAR Outcomes Study Achieved 90% MACE Accumulation in February 2022 – – U.S. Net Product Revenue of NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets Grew 12% Seq...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, which can be found on our investor relations website . Jefferies Global Healthcare Confer...